Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DrugSynergy

Financiado

Cerrado

DrugSynergy A data driven systems biology approach to optimize drug combination...

DrugSynergy A data driven systems biology approach to optimize drug combination strategies The complex physiopathology of human chronic diseases includes networks robustness, feedback loops, and cross-talks, which may induce limited efficacy, resistance, and/or excessive toxicity of an individual drug. Learning how to c... ver más

28/02/2018

INSTITUT CURIE FON...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-02-28

ERC-PoC-2015: ERC Proof of Concept Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

INSTITUT CURIE FONDATION

150.00K€ | Lider

ELECTRICIDAD GOROSABEL

724.26K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FJC2021-047611-I Multidisciplinary strategy for new drug discovery 65K€ Cerrado

ORBITO Oral biopharmaceutics tools 25M€ Cerrado

SYNEBIO High-throughput combinatory drugs testing on in vitro 3D cel... 150K€ Cerrado

SAF2014-53977-R HERRAMIENTAS DE RMN PARA EL DESARROLLO DE UNA PLATAFORMA PAR... Cerrado

INNOVABALT Strengthening the research and innovation capacities of the... 5M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2016-08-04
Fecha Fin: 2018-02-28

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The complex physiopathology of human chronic diseases includes networks robustness, feedback loops, and cross-talks, which may induce limited efficacy, resistance, and/or excessive toxicity of an individual drug. Learning how to combine drugs in order to improve treatment efficacy and lower undesired toxicity is a major biomedical challenge. Current strategies for drug repositioning and optimization of drug combinations have two man limitations: 1) they mostly use public data and databases, which are based on knowledge of individual drug stimuli and do not specifically analyze interactions, 2) they consider limited number of cellular outputs to analyze the response to a drug. In DrugSynergy, we will use an innovative systems biology large-scale data-driven approach to determine the interaction between two drugs at the highest possible resolution. Our computational analysis workflow has been extensively validated over the past years. It is now robust enough to be applied for the optimization of drug combinations. Our business development strategies will follow several possible non-exclusive scenarios: 1) service providing to pharmaceutical and biotech companies to optimize their own pipeline of drug combinations, 2) generate intellectual property (IP) through identification of new drug combinations, optimization of existing drug combinations by addition of innovative drugs through screening of small molecule libraries, including from our Institute. These goals will be achieved in an academic structure, through licensing new IP to industrial partners, or within a start-up company created around the innovative pipelines and know-how of DrugSynergy. These options will be explored with our business development and industrial partnership department. DrugSynergy is expected to have a strong biomedical and socio-economic impact because of the growing need of efficiently combine multiple drugs to address health challenges such as cancer and chronic inflammatory diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores